A study comparing once daily versus an itch based multiple times Ddaily application of a superpotent steroid cream in lichen simplex chronicus

A randomised controlled trial comparing once daily versus itch-based multiple daily application of clobetasol propionate 0.05% cream in lichen simplex chronicus

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/10/046885

Enrollment

Registered

2022-10-28

Start date

Unknown

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L280- Lichen simplex chronicus

Interventions

Intervention1: Multiple daily application of clobetasol propionate 0.05 % cream: Clobetasol propionate, a super potent topical corticosteroid is applied multiple times based on the urge of the patient

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with clinical diagnosis of lichen simplex chronicus 2.More than 18 years of age 3.Patients with well circumscribed lesions of lichen simplex chronicus.

Exclusion criteria

Exclusion criteria: 1.Use of systemic medications for treatment of other diseases which may act on the lesion 2.Lichen simplex chronicus due to underlying systemic or dermatological diseases 3.Lichen simplex chronicus superimposed on any other skin lesions 4.Lichen simplex chronicus of the anogenital region 5.Patients who do not consent for study or follow up 6.Pregnant and lactating females.

Design outcomes

Primary

Measure	Time frame
Change in the grade of lichenification of the lesion and change in 5 D pruritus scoreTimepoint: At the end of 16 weeks	—

Secondary

Measure	Time frame
To assess the change in area of lesion in patients with lichen simplex chronicus who are applying clobetasol propionate cream 0.05% once daily versus itch-based multiple times daily application.Timepoint: At the end of 16 weeks;To assess the change in ItchyQol in patients with lichen simplex chronicus who are applying clobetasol propionate cream 0.05% once daily versus itch-based multiple times daily application.Timepoint: At the end of 16 weeks;To assess the change in VAS in patients with lichen simplex chronicus who are applying clobetasol propionate cream 0.05% once daily versus itch-based multiple times daily application.Timepoint: At the end of 16 weeks;To assess the side effects of topical corticosteroids in patients with lichen simplex chronicus who are applying clobetasol propionate cream 0.05% once daily versus itch-based multiple times daily application.Timepoint: At the end of 16 weeks	—

Measure

Time frame

To assess the change in area of lesion in patients with lichen simplex chronicus who are applying clobetasol propionate cream 0.05% once daily versus itch-based multiple times daily application.Timepoint: At the end of 16 weeks;To assess the change in ItchyQol in patients with lichen simplex chronicus who are applying clobetasol propionate cream 0.05% once daily versus itch-based multiple times daily application.Timepoint: At the end of 16 weeks;To assess the change in VAS in patients with lichen simplex chronicus who are applying clobetasol propionate cream 0.05% once daily versus itch-based multiple times daily application.Timepoint: At the end of 16 weeks;To assess the side effects of topical corticosteroids in patients with lichen simplex chronicus who are applying clobetasol propionate cream 0.05% once daily versus itch-based multiple times daily application.Timepoint: At the end of 16 weeks

—

Countries

India

Contacts

Public ContactSree Parvathy V

All India Institute of Medical Sciences

binodkhaitan@hotmail.com01126588500

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026